Latest In Research

The good news is that treatment options for lung cancer patients are rapidly improving. In the last two years, more treatments have been approved by the United States Food and Drug Administration (FDA) for the treatment of lung cancer than had been approved in the prior ten years. New and life saving treatments, along with clinical trials, are happening rapidly and LCFA is committed to keeping you up to date on the latest, most hopeful and helpful, information.

12/12
2017

Active Therapeutic Thoracic Trials – December 2017

The Ohio State University Cancer Research Center was established in 1973 and received National Cancer Institute designation in April 1976 as a comprehensive cancer center (OSUCCC). The patient care arm of the OSUCCC is the Arthur G. James C…

12/5
2017

FDA grants approval for in vitro diagnostic

Detecting genetic mutations in vitro: On November 30, 2017, the Food and Drug Administration granted marketing approval to the FoundationOne CDx (F1CDx, Foundation Medicine, Inc.), a next generation sequencing (NGS) based in vitro diagn…

11/17
2017

Dr. Garon on Immunotherapy as Salvage Treatment for Advanced Lung Cancer

from OncLive Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses the possibility of administering PD-1 or PD-L1 blockades as a third-line or salvage therapy for patients with a…

11/17
2017

Liquid Biopsies: A Lung Cancer Game-Changer?

In early 2016, Matthew Tobin came down with a headache and persistent cough that lasted for months. When his doctor ordered an X-ray to test for pneumonia, it revealed a spot on his lung. After a tissue biopsy, doctors gave him the devastat…

11/16
2017

Active Therapeutic Thoracic Trials – November 2017

The Ohio State University Cancer Research Center was established in 1973 and received National Cancer Institute designation in April 1976 as a comprehensive cancer center (OSUCCC). The patient care arm of the OSUCCC is the Arthur G. James C…

11/15
2017

Tumor Mutation Burden Shows Promise as a Response Biomarker in Small Cell Lung Cancer

Tumor Mutation Burden Shows Promise in Small Cell Lung Cancer From The ASCO Post: Patients with small cell lung cancer (SCLC) and a high tumor mutation burden had a near doubling in response rate and 1-year overall survival when ipilimuma…

11/14
2017

LCFA trio contribute to ‘cancer interception’ project

From EurekAlert: Developing diagnostic tools to "intercept" lung cancer at its earliest stage is the goal of a research team led by Boston University School of Medicine (BUSM), along with colleagues at the University of California, Los Angel…

11/7
2017

Alecensa Approved as First-Line Treatment

From Yahoo Finance: Alecensa Approved as First-Line Treatment for People With Specific Type of Lung Cancer The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Appl…

11/7
2017

Immunotherapy for Lung Cancers: First-Line and Beyond

Immunotherapy for Lung Cancers From Medscape: This roundtable discussion on important issues in immunotherapy for lung cancer was filmed at the American Society of Clinical Oncology (ASCO) 2017 annual meeting in Chicago on June 4. H. Jack …

11/7
2017

iSABR Trial for Early-Stage, Unresectable NSCLC Now Open

iSABR Trial Now Open from UCLA October, 2017 Patient Newsletter A new randomized, phase 1/2 study of stereotactic ablative body radiotherapy with or without durvalumab is now open to enrollment at UCLA Main Campus. Stereotactic abla…

Research is imperative to improve treatment and management of all diseases and that’s particularly true of lung cancer. It’s creation of new knowledge, it’s discovery. It’s how we learn how to improve management of symptoms, to improve survival. ~Dr. David Johnson